Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07111572
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
RecruitingOBSERVATIONAL
Trial Details
Start: 2025-08-01Est. Completion: 2026-08-01
Enrollment target: 100 participants Locations- Qilu Hospital of Shandong University, Jinan, Shandong, China
Other microbiome trials you might be interested in
Ulcerative Colitis (UC)
This study will evaluate the efficacy and safety of 627 in patients with UC.
Guangzhou, ChinaEst. completion Feb 28, 2029
Ulcerative ColitisInflammatory Bowel DiseasesColitisColitis, Ulcerative
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active…
Canoga Park, United StatesEst. completion Jun 2027